Much like the reflected glory of working in an institution with Nobel prize-winners, I am basking in the reflected glory of working at an institution that has more or less successfully applied gene therapy to alleviate the suffering of children with incurable genetic diseases. And they’re fighting the good fight, because sometimes, they win.
Luigi Naldini wrote, in his Perspective:
[This study is] the successful first clinical testing of an HIV-derived vector in hematopoietic stem cell (HSC)–based gene therapy. The procedure was used to treat a severe neurodegenerative disease, X-linked adrenoleukodystrophy (ALD), and the results indicate stable expression of a therapeutic gene in a substantial fraction of patients’ hematopoietic cells, as well as clinical benefits.
Why was it so necessary to use gene therapy as opposed to other cutting edge tools? First, the setting. In the words of the authors:
The ALD protein participates in the peroxisomal degradation of very-long-chain fatty acids (VLCFAs) in oligodendrocytes and microglia, and deficiency of this protein disrupts myelin maintenance by these cells. Affected boys enter a phase of active multifocal brain demyelination when they are 6 to 8 years old. Most die before reaching adolescence.
It makes one quail. Your little boy starts school, is perfectly normal, and then the nightmare begins… “In untreated ALD patients, the decline of performance and verbal functions is inevitably continuous and devastating during the first 2 years after the onset of inflammatory demyelinating lesions.”
Second, the only other possible treatment is to find an allogenic bone marrow donor. We all know how difficult and random that can be. After that, and if the lesions are not too advanced, the child has to survive the graft and it has to take, none of which are givens. Thus, successfully validated gene therapy is true hope for a previously hopeless situation.
The authors were very careful to not publish their results immediately but have been following their treated patients for the last two years. They have applied a technique to make sure that the treated cells of the immune system, which then infiltrate brain tissue and act as portable garbage removers of the VLCFAs, remain stable and display no warning signs that they could become cancerous. One of those signs could be that only one or a few engineered cells survive and multiply unduly.
They used a delightfully modern technique of high-throughput sequencing to make sure that there were lots of different sites of insertion of the therapeutic vector present in the circulating blood cells, and that that diversity did not diminish over time.
The treatment is at least as good as bone marrow transplantation in preventing additional degradation. In part of the brain of one of the patients, there was actually reversal, “a process that does not occur spontaneously in ALD.”
Two seven-year-old boys clearly benefited from this new technique. May there be many more.
Finally, the discussion concludes, rightly:
HSC gene therapy might also be considered as a therapeutic option for adult ALD patients who develop cerebral demyelination, for whom the mortality risk of allogeneic HCT is ~40%.
Hooray for Marina, Alain, Patrick and all their collaborators! Hooray for these two little boys and their families!
-
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., Mahlaoui, N., Kiermer, V., Mittelstaedt, D., Bellesme, C., Lahlou, N., Lefrere, F., Blanche, S., Audit, M., Payen, E., Leboulch, P., l’Homme, B., Bougneres, P., Von Kalle, C., Fischer, A., Cavazzana-Calvo, M., & Aubourg, P. (2009). Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy Science, 326 (5954), 818-823 DOI: 10.1126/science.1171242









